COMPANY WORKBOOK · DXCM
DexCom, Inc.
Healthcare & Life Sciences · Medical Devices
$79.41-5.98%
60/100
INTERACTIVE PRICE CHART
Trend and moving averages
RELATIVE PERFORMANCE
DXCM versus SPY and SMH
Indexed to 100
Cross-sectional ranking
Scores are percentile-ranked against the current Young Bull universe and stored by date in PostgreSQL.
Healthcare & Life Sciences
This company is available as a market-data workbook. Young Bull has not added a manual investment thesis for it yet.
MODEL READ
Overall score: 59.8. Last ranked 2026-11-07.
QUARTERLY FUNDAMENTALS
Revenue and earnings power
TRAILING P/E31.26
PRICE / SALES5.80
EV / EBITDA19.48
BOOK VALUEN/A
GROSS MARGIN63.4%
PROFIT MARGIN19.4%
RETURN ON EQUITY37.7%
FREE CASH FLOW811.9M
What it does
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
PRIMARY SOURCES